Notable Insider Trading: Organovo Holdings, Inc. $ONVO

6bb0bfc556ab93b9b78eae29aa8a0044

Organovo Holdings, Inc. (ONVO) insider have most recently took part in a trading activity. On Nov 24, 2017 Murphy Keith, Former affiliate last filing bought 335,500 shares having total worth of $499,895 at the price of $1.49 per share, following the transaction a total of 6,373,673 shares owned by Murphy Keith.

Furthermore, over the past 12 months , the stock was traded 3 times by insiders. In 3 of these trades, the insider was a seller .

Shares of Organovo Holdings, Inc. (ONVO) traded up 9.27% on Dec 1, 2017, hitting $1.65. 2,447,770 shares of the company’s stock traded hands. Organovo Holdings, Inc. has a 52 week low of $1.37 and a 52 week high of $4.81. The company’s market cap is $420 million.

Organovo Holdings, Inc. (ONVO) last announced its earnings results on Nov 9, 2017. The company reported -0.09 earnings per share (EPS) for the quarter, higher than the consensus estimate of -0.10 by $0.01. The company had revenue of $1 million for the quarter, compared to the consensus estimate of $1 million. During the same quarter in the previous year, the company posted -0.10 earnings per share. The company’s revenue for the quarter was down 2% on a year-over-year basis.

2017-11-09 2017-08-09 2017-06-07 2017-02-09 2016-11-03 2016-08-04 2016-06-09 2016-02-08 2015-11-09 2015-08-10
earnings per share -0.09 -0.10 -0.10 -0.09 -0.10 -0.09 -0.09 -0.11 -0.12 -0.10
Revenue(M) 1.36 0.99 0.81 1.15 1.38 0.89 0.55 0.33 0.3 0.31

Organovo Holdings Inc., is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. The company’s NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types. Organovo’s NovoGen MMX Bioprinter was selected as one of the “Best Inventions of 2010” by TIME Magazine. Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development. Organovo’s bioprinting technology can also be developed to create surgical tissues direct therapy.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.